Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 13/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 9/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16947092 | 0.86 | NTRK1 (0.46) | NTRK1NTRK3NTRK2JAK2SCN9A | |
| SCHEMBL16936008 | 0.84 | NTRK1 (0.43) | NTRK1JAK2SCN9ATGFBR1ADORA3 | |
| SCHEMBL16946989 | 0.83 | NTRK1 (0.40) | NTRK1JAK2SCN9ATGFBR1ADORA3 | |
| SCHEMBL16946993 | 0.82 | NTRK1 (0.39) | NTRK1JAK2SCN9ATGFBR1ADORA3 | |
| SCHEMBL16946991 | 0.81 | NTRK1 (0.39) | NTRK1JAK2SCN9ATGFBR1ADORA3 | |
| SCHEMBL16946998 | 0.81 | NTRK1 (0.43) | NTRK1JAK2SCN9ATGFBR1 | |
| SCHEMBL19827027 | 0.78 | NTRK1 (0.40) | NTRK1JAK2SCN9ATGFBR1ADORA3 | |
| SCHEMBL19827028 | 0.78 | NTRK1 (0.39) | NTRK1NTRK3NTRK2JAK2TGFBR1 | |
| SCHEMBL21370428 | 0.78 | NTRK1 (0.39) | NTRK1NTRK3NTRK2JAK2TGFBR1 | |
| SCHEMBL19826941 | 0.78 | NTRK1 (0.39) | NTRK1NTRK3NTRK2JAK2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885NTRK3 1453/4885NTRK2 1039/4885 |
| US-10246466-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | NTRK1 1072/4885NTRK3 1453/4885NTRK2 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.